EP3331862A1 - Procédé de préparation de chlorhydrate d'ivabradine solide - Google Patents

Procédé de préparation de chlorhydrate d'ivabradine solide

Info

Publication number
EP3331862A1
EP3331862A1 EP16745772.0A EP16745772A EP3331862A1 EP 3331862 A1 EP3331862 A1 EP 3331862A1 EP 16745772 A EP16745772 A EP 16745772A EP 3331862 A1 EP3331862 A1 EP 3331862A1
Authority
EP
European Patent Office
Prior art keywords
ivabradine
process according
compound
acid
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16745772.0A
Other languages
German (de)
English (en)
Inventor
Bohumil Dymacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP3331862A1 publication Critical patent/EP3331862A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Definitions

  • the present invention relates to a process for preparation of a solid form of ivabradine hydrochloride preferably in the polymorphic form delta or delta-d.
  • the molecule of the formula (I) has one chiral carbon atom in position 7.
  • Ivabradine is the single (S) enantiomer.
  • ivabradine is present as a hydrochloride salt form.
  • Ivabradine hydrochloride was first disclosed in EP 534859. Crystalline ivabradine hydrochloride was obtained therein by treatment of ivabradine base with 0.1 N HC1 and recrystallization of the residual mass after evaporation of the mixture from acetonitrile in 55% yield.
  • Alfa-crystalline form is disclosed in US 7176197 and is obtainable by a crystallization of ivabradine hydrochloride from a toluene/ l-methyl-2-pyrrolidone mixture.
  • Beta-crystalline form is disclosed in US 2006/0194962 and is obtainable by
  • Gamma-crystalline form is disclosed in US 2006/0194963 and is obtainable by a crystallization of ivabradine hydrochloride from 2-ethoxyethanol, a mixture of 2- ethoxyethanol and water or a mixture of ethanol and water. This form is a hydrate and, if heated, it may be converted to the anhydrous gamma-d crystalline form as shown in US 2006/0194964.
  • EP 1775288 discloses the delta-form of crystalline ivabradine hydrochloride.
  • the product is prepared by a crystallization of the product of EP 534859 from acetonitrile and isolation of the crystalline product from the reaction mixture after 2 days standing by filtration and drying at ambient temperature.
  • the crystalline form delta is a hydrate comprising about 2.8% of water.
  • EP 1775287 discloses the dehydrated delta form (delta-d form) of crystalline ivabradine hydrochloride.
  • the product is prepared by crystallization of the product of EP 534859 from acetonitrile and isolation of the crystalline product from the reaction mixture after 2 days standing by filtration and heating of the solid product at 85°C for 4 hours.
  • the crystalline form delta-d is an anhydrous product.
  • Ivabradine can be prepared for example by the process as described in EP 534859. The process is depicted in the following scheme:
  • the Compound 3 (i.e. (S)-l-(3,4-dimethoxybicyclo[4.2.0]octa-l,3,5-trien-7-yl)-N- methylmethanamine) that is not consumed by reaction with 3-(3-halogenopropyl)-7,8- dimethoxy-lH-benzo[d]azepin-2(3H)-one remains in the reaction mixture and if not removed it will subsequently negatively affect the purity of the final ivabradine hydrochloride.
  • the removal of the Compound 3 from Compound 2 is not trivial.
  • EP 534859 discloses the use of chromatography for ivabradine purification. It is not desirable to use chromatography in production.
  • EP 2495237 discloses a purification procedure comprising derivatization of ivabradine and subsequent transformation of the derivative into ivabradine. The drawback of the procedure is the need for the use of additional chemical steps after ivabradine has been prepared.
  • the objective of the present invention is to provide an improved process yielding pure crystalline ivabradine hydrochloride, advantageously in delta or delta-d form, without employing toxic crystallization solvents.
  • the present invention relates to a process for the preparation of a solid form of ivabradine hydrochloride by reduction of Compound 2 or a salt thereof
  • aqueous solution sufficient to obtain a molar ratio ivabradine to acid between 1:0.001 and 1:0.2
  • the process can be followed by crystallization of ivabradine hydrochloride from the water immiscible solvent by adding an ethanolic solution of hydrochloric acid, preferably at room temperature, and optionally isolating solid ivabradine hydrochloride.
  • the present invention relates to a process for the preparation of a solid
  • aqueous solution sufficient to obtain a molar ratio ivabradine to acid between 1:0.001 and 1:0.2
  • the aqueous solvent used in the reduction is either water or a mixture of water and a water miscible solvent. Preferably, water is used.
  • the reduction is performed with a reduction catalyst.
  • the reduction catalyst can be for example Pd/C or Pd(OH) 2 /C, preferably
  • the concentration of Compound 2 in the aqueous solvent is between 6% (w/w) and 13% (w/w), preferably between 9% (w/w) and 11% (w/w).
  • the salt form of Compound 2 is preferably the hydrochloride salt.
  • the reduction is performed at a temperature between 30°C and 70°C, preferably between 45 and 55°C. Reduction is preferably done using gaseous hydrogen. The reduction is finished after the most of Compound 2 is transformed into ivabradine. It typically runs for 3-10 hours, preferably for 4-6 hours. After the reduction is finished, the reaction mixture is cooled to 20-35°C and the hydrogenation catalyst is filtrated off.
  • ivabradine is also obtained in the form of the salt.
  • the obtained salt of ivabradine is treated with a base, preferably a water solution of a base, to obtain a mixture of the free form of ivabradine and the aqueous solvent.
  • the mixture is extracted with a water immiscible solvent.
  • a base preferably a water solution of a base
  • ethyl acetate, isopropyl acetate, toluene or mixtures thereof are used.
  • the concentration of ivabradine in the water immiscible solvent is between 0.5 mmol/ml and 5 mmol/ml, preferably 1 mmol/ml and 3 mmol/ml, most preferably 1 mmol/ml.
  • the layers are separated and the water layer is disposed.
  • the water immiscible layer is washed with an acidic aqueous solution.
  • the amount of the acidic aqueous solution is sufficient to obtain a molar ratio ivabradine to acid between 1:0.001 and 1:0.2.
  • the acid used in the process can be both organic and inorganic acid capable of forming a salt with Compound 3.
  • the examples of the acids are hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, a solution of carbon dioxide in water (i.e.
  • carbonic acid preferably hydrochloric acid or a solution of carbon dioxide in water are used.
  • the molar ratio between ivabradine and the acid is between 1:0.001 and 1:0.2 depending on the type of the acid and the reaction scale.
  • strong acids for example hydrochloric acid
  • the ratio can be between 1:0.001 and 1:0.1, preferably between 1:0.001 and 1:0.06.
  • weak acids for example a solution of carbon dioxide in water, i.e. carbonic acid, preferably saturated solution of carbon dioxide in water
  • the ratio can be between 1:0.1 and 1:0.2.
  • ivabradine remains in the water immiscible solvent layer after the layers are separated.
  • the extraction step with a water immiscible solvent solution of ivabradine with the acidic aqueous solution can be optionally repeated.
  • the water immiscible solvent layers are mixed and concentrated, using for example distillation, to the final concentration of ivabradine in the solution between 8% (w/w) and 15% (w/w), preferably between 9% (w/w) and 11% (w/w).
  • Ivabradine can be optionally isolated from the water immiscible solvent (for example by precipitation or crystallization from the solvent or by distilling off of the solvent) or an ethanolic solution of hydrochloric acid can be added to the solution of ivabradine in the water immiscible solvent and ivabradine hydrochloride is crystallized from the solution.
  • the ethanolic solution of hydrochloric acid is added at a temperature between 15°C and 30°C, preferably between 19°C and 21°C.
  • the concentration of the ethanolic solution of hydrochloric acid is between 20% (w/w) and 30% (w/w), preferably between 26% (w/w) and 28% (w/w).
  • the molar ratio between ivabradine and hydrochloric acid is between 1: 1 and 1:2, preferably between 1: 1 and 1: 1.2.
  • the mixture is stirred for 1 to 10 hours, preferably for 2 to 4 hours.
  • the mixture can be cooled before ivabradine hydrochloride is isolated.
  • the mixture can be cooled at a temperature between -20 and 20°C.
  • the crystallized product is isolated from the mixture by using any conventional technique, e.g. filtering, centrifugation or distillation off the solvent.
  • Compound 2 or a salt thereof used as starting material in the process of the present invention can be prepared for example by the process as described in EP 534859, but the invention is not limited to such material.
  • the solid forms of ivabradine hydrochloride produced by the process of the present invention have an excellent batch-to-batch uniformity in the size and shape of the formed crystals and preferably comprises less than 10% of other crystalline forms of ivabradine hydrochloride.
  • the solid forms of ivabradine hydrochloride obtainable by the described processes may be formulated into pharmaceutical compositions, for instance to tablet compositions for oral administration, and may be used in medicine, for instance in a treatment of angina pectoris.
  • Compound 3 Compound 2. HCI 6.46 kg of 10% (w/w) solution of Compound 2.HC1 (containing 1.9% (HPLC IN) of
  • Isopropyl acetate solution (containing ivabradine containing 1.9% (HPLC IN) of Compound 3) was extracted with 0.6 kg of 0.07% (w/w) water solution of HC1 (molar ratio ivabradine: HC1 1:0.008). Phases were separated.
  • Compound 3 was extracted with 0.41 kg of 0.07% (w/w) water solution of HC1 (molar ratio ivabradine :HC1 1:0.006). Phases were separated.
  • the isopropyl acetate layer (containing ivabradine containing 0.66% (HPLC IN) of Compound 3) was extracted with 0.21 kg of 0.07% (w/w) water solution of HC1 (molar ratio ivabradine :HC1 1:0.003). Phases were separated.
  • ivabradine in isopropyl acetate 0.8 kg of ethanol, 0.16 kg of 27% (w/w) solution of HC1 in ethanol (molar ratio ivabradine :HC1 1: 1.1) and 0.5 kg of isopropyl acetate were added at 20°C. The mixture was stirred at this temperature for 3 hours. Solid ivabradine hydrochloride was filtered off.
  • Example 3 2 g of ivabradine hydrochloride prepared according to Example 1 were dried at 30°C for 4 hours to provide ivabradine hydrochloride form delta in 98% yield.
  • Example 3 2 g of ivabradine hydrochloride prepared according to Example 1 were dried at 30°C for 4 hours to provide ivabradine hydrochloride form delta in 98% yield.
  • ivabradine hydrochloride prepared according to Example 1 were dried at 50°C for 4 hours to provide ivabradine hydrochloride form delta-d in 98% yield.
  • ivabradine content of Compound 3 was 0.06% (HPLC IN)) in yield 80%.
  • Compound 3 Compound 2 5 g of Compound 2 (the content of Compound 3 was 0.95 % (HPLC IN)) in 2.5 ml of toluene were treated with 2.5 g of saturated water solution of carbon dioxide (0.1 equivalent to Compound 2) to provide two-layers system. The layers were separated. The water layer was washed with 0.5 ml of toluene. The toluene layers were mixed and washed with 2.5 g of saturated water solution of carbon dioxide (0.1 equivalent to Compound 2). The layers were separated and the organic layer was distilled off to provide Compound 2 (the content of Compound 3 was 0.03% (HPLC IN)) in yield 80%.
  • Scan step time between 0.2-2.0 seconds
  • Antiscatter slit 11.8 mm

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour la préparation d'une forme solide du chlorhydrate d'ivabradine par réduction du composé 2 ou d'un sel correspondant dans un solvant aqueux, suivie d'une extraction de l'ivabradine, l'extraction comprenant les étapes consistant à : 1) ajouter un solvant non miscible à l'eau, 2) séparer les phases, 3) laver la phase de solvant non miscible à l'eau avec une quantité d'une solution aqueuse acide suffisante pour obtenir un rapport molaire d'ivabradine à acide entre 1:0,001 et 1:0,2.
EP16745772.0A 2015-08-04 2016-08-03 Procédé de préparation de chlorhydrate d'ivabradine solide Withdrawn EP3331862A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179744 2015-08-04
PCT/EP2016/068577 WO2017021466A1 (fr) 2015-08-04 2016-08-03 Procédé de préparation de chlorhydrate d'ivabradine solide

Publications (1)

Publication Number Publication Date
EP3331862A1 true EP3331862A1 (fr) 2018-06-13

Family

ID=53776476

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16745772.0A Withdrawn EP3331862A1 (fr) 2015-08-04 2016-08-03 Procédé de préparation de chlorhydrate d'ivabradine solide

Country Status (2)

Country Link
EP (1) EP3331862A1 (fr)
WO (1) WO2017021466A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107200710A (zh) * 2017-05-22 2017-09-26 苏州华健瑞达医药技术有限公司 盐酸伊伐布雷定新晶型、制备方法及含有其的组合物
IT202000025312A1 (it) * 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
WO2014114341A1 (fr) * 2013-01-24 2014-07-31 Synthon Bv Procédé de préparation d'ivabradine
ITMI20130830A1 (it) * 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa Procedimento per la preparazione di ivabradina

Also Published As

Publication number Publication date
WO2017021466A1 (fr) 2017-02-09

Similar Documents

Publication Publication Date Title
EP2300479B1 (fr) Chlorhydrate de nalmefene dihydraté
WO2008012105A1 (fr) Forme cristalline d'erlobtinib
AU2007298855A1 (en) Process for preparing N-alkyl naltrexone halides
US8378106B2 (en) Method for preparing argatroban monohydrate and a process for its synthesis
EP2346846A1 (fr) Formes anhydrates et hydrates de ranélate de strontium
EP2948432B1 (fr) Procédé de préparation d'ivabradine
EP3331862A1 (fr) Procédé de préparation de chlorhydrate d'ivabradine solide
US10017472B2 (en) Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same
WO2014097306A1 (fr) Forme polymorphe stable et pure du bortézomib
WO2012025940A1 (fr) Forme polymorphe du chlorhydrate d'ivabradine et son procédé de préparation
WO2015111085A2 (fr) Procédés de préparation d'eltrombopag et sels pharmaceutiquement acceptables, solvates et intermédiaires de celui-ci
CN106810542B (zh) 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
EP2189461B1 (fr) Hydrochlorure crystalline d'irinotecan et procédés pour sa préparation
EP3347345B1 (fr) Solvate mixte de (r)-5-[2-(5,6-diéthylindan-2-ylamino)-1-hydroxyéthyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
WO2012070066A1 (fr) Procédé de préparation de taurolidine et de produits intermédiaires de celle-ci
US20080146805A1 (en) Process for the Production of Levorphanol and Related Compounds
EP2032581B1 (fr) Composés enrichis en énantiomères et procédé
WO2013170242A1 (fr) Forme 2 de polymorphe de 7-(tert-butyl-d9)-3-(2,5-difluorophényl)-6-((1-méthyl-1h-1,2,4-triazol-5-yl)méthoxy)-[1,2,4]triazolo[4,3-b]pyridazine
EP2260037A2 (fr) Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine
EP3083629B1 (fr) Procede de preparation de vardenafil et ses sels
WO2010010058A1 (fr) Méthode de préparation de chlorhydrate d'alfuzosine anhydre
WO2022090138A1 (fr) Procédés de préparation de polymorphes d'ivabradine hci
WO2022035434A1 (fr) Co-cristal de varénicline et d'acide oxalique, composition pharmaceutique correspondante et méthodes d'utilisation correspondantes
CN110964014A (zh) 利格列汀中间体的晶型及其制备方法
WO2013170241A1 (fr) Polymorphes de 7-(tert-butyl-d9)-3-(2,5-difluorophényl)-6-((1-méthyl-1 h-1,2,4-triazol-5-yl)méthoxy)-[1,2,4] triazolol[4,3-b] pyridazine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20190204

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200605

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SYNTHON B.V.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DYMACEK, BOHUMIL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201016